News | March 25, 2011

Vital Images and Bayer HealthCare Diagnostics Arrange Collaboration

March 25, 2011 – The diagnostic imaging business unit of Bayer Vital GmbH and Vital Images, have signed a cooperation agreement. The agreement’s objective is to conduct joint activities that will introduce radiologists in Germany to the combination of appropriate software and contrast agents.

“Rapid developments in advanced visualization software used with state-of-the-art MRI and CT imaging techniques are delivering a huge amount of additional information,” said Robert Hite, head of the diagnostic imaging business in Germany. “This is presenting the evaluating radiologists with the challenge of efficiently selecting the right information from the constantly growing volume of image data. Both image processing software and contrast agents greatly assist diagnostic efficiency and when used in tandem could deliver substantial benefits for the evaluating radiologist. If we can coordinate the two techniques better, it could lead to considerable synergies to the benefit of the radiologist.”

“We are excited by our groundbreaking collaboration with Bayer in Germany and feel it will help grow our global business and development activities,” said Michael H. Carrel, CEO Vital Images. “This is a truly unique collaboration involving visualization with contrast agents and we are confident that, with Bayer, we have found the right partner to make this kind of collaboration a success.”

For more information: www.vitalimages.com

Related Content

ISMRM Issues Guidelines for MRI Gadolinium Contrast Agents
News | Contrast Media | August 15, 2017
The International Society for Magnetic Resonance in Medicine (ISMRM) has provided new guidance in the use of contrast...
Contrast Media from Bayer, trends in contrast media and developments in contrast media
Feature | Contrast Media | July 28, 2017 | By Dave Fornell
Here are several updates in medical imaging ...
Guerbet Announces Plans to Streamline Contrast Media Portfolio, gadolinium MRI contrast
News | Contrast Media | July 18, 2017
July 18, 2017 — Guerbet recently announced that it will phase out sales throughout the world of two products: Hexabri
ACR Offers Revised Contrast Media in Imaging Manual
News | Contrast Media | July 17, 2017
The American College of Radiology (ACR) recently revised its authoritative guide for the safe and effective use of...
FDA says gadolinium retention in the brain is not a safety issue
Feature | Magnetic Resonance Imaging (MRI) | May 25, 2017
A U.S. Food and Drug Administration (FDA) review of the safety ramifications of gadolinium-based contrast agents for...
Targeted MRI Could Pinpoint Aggressive Prostate Cancers Before They Spread

The ZD2-Gd probe, represented by the orange ball and green arrow, binds to the EDB-FN in the prostate cancer cells with high metastatic potential. This results in a strong MRI signal (upper right). Prostate cancer cells with low metastatic potential have no EDB-FN and so there is no MRI signal (lower right). Credit: Han, et al., Bioconjug Chem-Apr-2017

News | Prostate Cancer | May 24, 2017
A research team funded by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) has engineered a...
Scientists Develop Novel Chemical Dye to Improve MRI Liver Cancer Imaging
News | Magnetic Resonance Imaging (MRI) | May 03, 2017
May 3, 2017 — Scientists from the National University of Singapore (NUS) have developed a novel nanodiamond-based ...
Sponsored Content | Case Study | Contrast Media Injectors | April 13, 2017
The volume of computed tomography (CT) imaging exams continues to grow in the United States,[2] adding pressure to...
PRAC, European Medicines Agency, gadolinium-based contrast agents, safety recommendations, brain MRI
News | Contrast Media | March 13, 2017
The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency recently released new...
Overlay Init